Eli Lilly (LLY) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Eli Lilly Revenue Highlights

Latest Revenue (Y)

$65.18B

Latest Revenue (Q)

$19.80B

Main Segment (Y)

Product

Main Geography (Y)

UNITED STATES

Eli Lilly Revenue by Period

Eli Lilly Revenue by Year

Date	Revenue	Change
2025-12-31	$65.18B	44.70%
2024-12-31	$45.04B	32.00%
2023-12-31	$34.12B	19.56%
2022-12-31	$28.54B	0.79%
2021-12-31	$28.32B	15.40%
2020-12-31	$24.54B	9.95%
2019-12-31	$22.32B	3.84%
2018-12-31	$21.49B	7.61%
2017-12-31	$19.97B	-5.88%
2016-12-31	$21.22B	6.33%
2015-12-31	$19.96B	1.75%
2014-12-31	$19.62B	-15.13%
2013-12-31	$23.11B	2.25%
2012-12-31	$22.60B	-6.93%
2011-12-31	$24.29B	5.25%
2010-12-31	$23.08B	5.68%
2009-12-31	$21.84B	7.19%
2008-12-31	$20.37B	9.33%
2007-12-31	$18.63B	18.75%
2006-12-31	$15.69B	7.14%
2005-12-31	$14.65B	5.68%
2004-12-31	$13.86B	10.14%
2003-12-31	$12.58B	13.59%
2002-12-31	$11.08B	-4.03%
2001-12-31	$11.54B	6.26%
2000-12-31	$10.86B	8.59%
1999-12-31	$10.00B	8.29%
1998-12-31	$9.24B	15.64%
1997-12-31	$7.99B	14.14%
1996-12-31	$7.00B	3.47%
1995-12-31	$6.76B	18.42%
1994-12-31	$5.71B	-11.48%
1993-12-31	$6.45B	-

Eli Lilly generated $65.18B in revenue during NA 2025, up 44.70% compared to the previous quarter, and up 265.61% compared to the same period a year ago.

Eli Lilly Revenue by Quarter

Date	Revenue	Change
2026-03-31	$19.80B	2.63%
2025-12-31	$19.29B	9.61%
2025-09-30	$17.60B	13.13%
2025-06-30	$15.56B	22.23%
2025-03-31	$12.73B	-5.94%
2024-12-31	$13.53B	18.30%
2024-09-30	$11.44B	1.21%
2024-06-30	$11.30B	28.91%
2024-03-31	$8.77B	-6.26%
2023-12-31	$9.35B	-1.53%
2023-09-30	$9.50B	14.27%
2023-06-30	$8.31B	19.43%
2023-03-31	$6.96B	-4.68%
2022-12-31	$7.30B	5.19%
2022-09-30	$6.94B	6.99%
2022-06-30	$6.49B	-16.93%
2022-03-31	$7.81B	-2.37%
2021-12-31	$8.00B	18.12%
2021-09-30	$6.77B	0.49%
2021-06-30	$6.74B	-0.96%
2021-03-31	$6.81B	-8.53%
2020-12-31	$7.44B	29.60%
2020-09-30	$5.74B	4.39%
2020-06-30	$5.50B	-6.15%
2020-03-31	$5.86B	-4.16%
2019-12-31	$6.11B	11.64%
2019-09-30	$5.48B	-2.84%
2019-06-30	$5.64B	10.69%
2019-03-31	$5.09B	-20.91%
2018-12-31	$6.44B	21.33%
2018-09-30	$5.31B	-4.98%
2018-06-30	$5.58B	12.51%
2018-03-31	$4.96B	-19.43%
2017-12-31	$6.16B	8.88%
2017-09-30	$5.66B	-2.86%
2017-06-30	$5.82B	11.40%
2017-03-31	$5.23B	-9.24%
2016-12-31	$5.76B	10.96%
2016-09-30	$5.19B	-3.94%
2016-06-30	$5.40B	11.09%
2016-03-31	$4.87B	-9.50%
2015-12-31	$5.38B	8.39%
2015-09-30	$4.96B	-0.38%
2015-06-30	$4.98B	7.19%
2015-03-31	$4.64B	-9.31%
2014-12-31	$5.12B	5.04%
2014-09-30	$4.88B	-1.22%
2014-06-30	$4.94B	5.39%
2014-03-31	$4.68B	-19.38%
2013-12-31	$5.81B	0.63%
2013-09-30	$5.77B	-2.65%
2013-06-30	$5.93B	5.85%
2013-03-31	$5.60B	-5.97%
2012-12-31	$5.96B	9.44%
2012-09-30	$5.44B	-2.81%
2012-06-30	$5.60B	-0.02%
2012-03-31	$5.60B	-7.35%
2011-12-31	$6.05B	-1.65%
2011-09-30	$6.15B	-1.68%
2011-06-30	$6.25B	7.08%
2011-03-31	$5.84B	-5.62%
2010-12-31	$6.19B	9.41%
2010-09-30	$5.65B	-1.63%
2010-06-30	$5.75B	4.80%
2010-03-31	$5.49B	-7.56%
2009-12-31	$5.93B	6.69%
2009-09-30	$5.56B	5.09%
2009-06-30	$5.29B	4.87%
2009-03-31	$5.05B	-3.14%
2008-12-31	$5.21B	0.02%
2008-09-30	$5.21B	1.15%
2008-06-30	$5.15B	7.13%
2008-03-31	$4.81B	-7.36%
2007-12-31	$5.19B	-

Eli Lilly generated $19.80B in revenue during Q1 2026, up 2.63% compared to the previous quarter, and up 146.30% compared to the same period a year ago.

Eli Lilly Revenue Breakdown

Eli Lilly Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Collaboration and Other Revenue	$4.22B	$4.29B	$5.31B	$3.08B	$2.36B
Product	$60.96B	$40.75B	$28.81B	$25.46B	$25.96B
Royalty	-	-	-	$163.40M	$175.00M
Trajenta (BI)	-	-	-	$383.70M	-
COVID-19 Antibodies	-	-	-	-	$2.24B

Eli Lilly's latest annual revenue breakdown by segment (product or service), as of Dec 25: Product (93.52%), and Collaboration and Other Revenue (6.48%).

Quarterly Revenue by Product

Product/Service	Mar 26	Sep 25	Jun 25	Mar 25	Sep 24	Mar 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
Neuroscience	$382.00M	$315.70M	$344.00M	$272.10M	$351.80M	$389.10M	$1.77B	-	-	-	-	-	-	-	-	-	-	-	-	-
Oncology	$2.27B	$2.41B	$2.41B	$1.95B	$2.23B	$1.81B	$1.75B	-	-	-	-	-	-	-	-	-	-	-	-	-
Cardiometabolic Health	$15.76B	$13.18B	$11.34B	$9.21B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Immunology	$1.20B	$1.36B	$1.26B	$1.09B	$1.19B	$834.00M	$986.90M	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Product, Total	-	$337.20M	$201.50M	$212.90M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product	-	-	-	$11.60B	$6.98B	$6.24B	$6.34B	$6.12B	$5.87B	$7.13B	$7.38B	$6.07B	$6.32B	$6.93B	$5.28B	$5.08B	-	-	-	-
Collaboration and Other Revenue	-	-	-	$1.13B	$1.33B	$721.80M	$962.00M	$822.40M	$617.10M	$677.10M	$621.50M	$669.60M	$485.60M	$507.50M	$459.50M	$421.70M	-	-	-	-
Other Product	-	-	-	-	$53.20M	$41.30M	$42.90M	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Immunology	-	-	-	-	-	-	$11.40M	-	-	-	-	-	-	-	-	-	-	-	-	-
Cialis	-	-	-	-	-	-	$86.80M	-	-	-	-	-	-	-	-	-	-	-	-	-
Zyprexa	-	-	-	-	-	-	$1.48B	-	-	-	-	-	-	-	-	-	-	-	-	-
Verzenio	-	-	-	-	-	-	$1.04B	-	-	-	-	-	-	-	-	-	-	-	-	-
Trulicity	-	-	-	-	-	-	$1.67B	-	-	-	-	-	-	-	-	-	-	-	-	-
Taltz	-	-	-	-	-	-	$744.20M	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Oncology	-	-	-	-	-	-	$275.40M	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Neuroscience	-	-	-	-	-	-	$118.20M	-	-	-	-	-	-	-	-	-	-	-	-	-
Diabetes	-	-	-	-	-	-	$4.72B	-	-	-	-	-	-	-	-	-	-	-	-	-
Erbitux	-	-	-	-	-	-	$153.90M	-	-	-	-	-	-	-	-	-	-	-	-	-
Cyramza	-	-	-	-	-	-	$224.10M	-	-	-	-	-	-	-	-	-	-	-	-	-
COVID-19 Antibodies	-	-	-	-	-	-	-	$1.06B	$217.10M	-	-	-	-	-	-	-	-	-	-	-
Basaglar	-	-	-	-	-	-	$179.60M	-	-	-	-	-	-	-	-	-	-	-	-	-
Baqsimi	-	-	-	-	-	-	$13.10M	-	-	-	-	-	-	-	-	-	-	-	-	-
Alimta	-	-	-	-	-	-	$53.50M	-	-	-	-	-	-	-	-	-	-	-	-	-
Olumiant	-	-	-	-	-	-	$231.40M	$406.90M	-	-	-	-	-	-	-	-	-	-	-	-
Other Diabetes	-	-	-	-	-	-	$141.90M	-	-	-	-	-	-	-	-	-	-	-	-	-
Mounjaro	-	-	-	-	-	-	$1.41B	-	-	-	-	-	-	-	-	-	-	-	-	-
Jardiance	-	-	-	-	-	-	$700.80M	-	-	-	-	-	-	-	-	-	-	-	-	-
Humulin	-	-	-	-	-	-	$206.70M	-	-	-	-	-	-	-	-	-	-	-	-	-
Humalog	-	-	-	-	-	-	$395.40M	-	-	-	-	-	-	-	-	-	-	-	-	-
Forteo	-	-	-	-	-	-	$146.40M	-	-	-	-	-	-	-	-	-	-	-	-	-
Emgality	-	-	-	-	-	-	$168.50M	-	-	-	-	-	-	-	-	-	-	-	-	-
Royalty	-	-	-	-	-	-	-	$30.30M	$25.10M	$32.50M	$43.30M	$34.40M	$53.20M	$38.90M	$31.00M	$43.00M	$34.10M	$31.50M	$34.70M	-
Trajenta (BI)	-	-	-	-	-	-	-	$103.60M	$85.80M	$90.70M	$103.80M	$92.60M	$96.10M	-	-	-	-	-	-	-
TYVYT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$125.60M	-	-	-	-	-

Eli Lilly's latest quarterly revenue breakdown by segment (product or service), as of Mar 26: Cardiometabolic Health (80.35%), Oncology (11.56%), Immunology (6.13%), and Neuroscience (1.95%).

Eli Lilly Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 25	Dec 24	Dec 23	Dec 22
Non-US	$6.06B	$4.27B	-	-
JAPAN	$2.13B	$1.81B	$1.75B	-
UNITED STATES	$43.48B	$30.38B	$18.19B	-
CHINA	$1.95B	$1.66B	$1.45B	-
Europe	$11.56B	$6.92B	$6.17B	$4.30B
Other Foreign Countries	-	-	$2.95B	$2.85B
United States	-	-	$21.79B	-
China	-	-	$1.54B	-
Japan	-	-	$1.67B	-

Eli Lilly's latest annual revenue breakdown by geography, as of Dec 25: UNITED STATES (66.71%), Europe (17.73%), Non-US (9.29%), JAPAN (3.27%), and CHINA (2.99%).

Quarterly Revenue by Country

Country	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
Europe	$3.65B	$3.10B	$3.50B	$2.57B	$2.39B	$3.85B	$1.63B	$1.44B	$1.34B	$2.57B	$1.18B	$1.09B	$1.07B	$1.06B	$1.10B	$1.07B	$1.15B	$1.10B	$1.21B	$1.32B
JAPAN	$571.00M	$654.10M	$554.70M	$521.00M	$402.20M	$1.02B	$429.10M	$363.90M	$439.00M	$390.80M	$455.60M	$387.20M	$395.00M	$487.70M	$454.40M	$410.20M	$534.80M	$595.00M	$665.40M	$571.80M
Non-US	$10.45B	$2.19B	$1.69B	$1.18B	$997.40M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
CHINA	$693.00M	$473.90M	$560.40M	$465.90M	$450.80M	$824.30M	$459.90M	$376.20M	$377.20M	$390.80M	$399.00M	$372.70M	$350.80M	$343.40M	$352.10M	$406.50M	$376.40M	$400.30M	$522.50M	$362.20M
UNITED STATES	$12.12B	$12.88B	$11.30B	$10.81B	$8.49B	$16.87B	$7.81B	$5.69B	$6.46B	$5.37B	-	-	-	-	-	-	-	-	-	-
Cardiometabolic Health	-	-	-	-	$9.21B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Product, Total	-	-	-	-	$212.90M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Oncology	-	-	-	-	$1.95B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Neuroscience	-	-	-	-	$272.10M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Immunology	-	-	-	-	$1.09B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Foreign Countries	-	-	-	-	-	-	$1.11B	$892.90M	$744.30M	$780.30M	$748.50M	$673.10M	$822.90M	$632.00M	$645.70M	$751.50M	$765.50M	$689.40M	$638.10M	$609.10M

Eli Lilly's latest quarterly revenue breakdown by geography, as of Mar 26: UNITED STATES (44.10%), Non-US (38.03%), Europe (13.27%), CHINA (2.52%), and JAPAN (2.08%).

Eli Lilly Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
NVO	Novo Nordisk	$232.26B	$65.35B
JNJ	Johnson & Johnson	$94.19B	$24.06B
LLY	Eli Lilly and	$65.18B	$19.80B
MRK	Merck	$65.01B	$16.29B
PFE	Pfizer	$62.58B	$14.45B
ABBV	AbbVie	$61.16B	$15.00B
AZN	AstraZeneca	$54.07B	$15.19B
NVS	Novartis	$46.66B	$11.83B
SNY	Sanofi	$43.07B	$11.12B
AMGN	Amgen	$36.75B	$9.56B
GILD	Gilead Sciences	$29.44B	$6.96B

LLY Revenue FAQ

What is Eli Lilly’s yearly revenue?

Eli Lilly's yearly revenue for 2025 was $65.18B, representing an increase of 44.70% compared to 2024. The company's yearly revenue for 2024 was $45.04B, representing an increase of 32.00% compared to 2023. LLY's yearly revenue for 2023 was $34.12B, representing an increase of 19.56% compared to 2022.

What is Eli Lilly’s quarterly revenue?

Eli Lilly's quarterly revenue for Q1 2026 was $19.8B, a 2.63% increase from the previous quarter (Q4 2025), and a 55.55% increase year-over-year (Q1 2025). The company's quarterly revenue for Q4 2025 was $19.29B, a 9.61% increase from the previous quarter (Q3 2025), and a 42.56% increase year-over-year (Q4 2024). LLY's quarterly revenue for Q3 2025 was $17.6B, a 13.13% increase from the previous quarter (Q2 2025), and a 53.87% increase year-over-year (Q3 2024).

What is Eli Lilly’s revenue growth rate?

Eli Lilly's revenue growth rate for the last 3 years (2023-2025) was 91.01%, and for the last 5 years (2021-2025) was 130.16%.

What are Eli Lilly’s revenue streams?

Eli Lilly's revenue streams in c 25 are Collaboration and Other Revenue, and Product. Collaboration and Other Revenue generated $4.22B in revenue, accounting 6.48% of the company's total revenue, down -1.72% year-over-year. Product generated $60.96B in revenue, accounting 93.52% of the company's total revenue, up 49.60% year-over-year.

What is Eli Lilly’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Eli Lilly was Product. This segment made a revenue of $60.96B, representing 93.52% of the company's total revenue.